Madrigal Pharmaceuticals Non Current Liabilities Other Over Time
| MDGL Stock | USD 328.19 3.26 0.98% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Madrigal Pharmaceuticals Performance and Madrigal Pharmaceuticals Correlation. Madrigal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.04) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Liabilities Other Analysis
Compare Madrigal Pharmaceuticals and related stocks such as Intercept Pharmaceuticals, TG Therapeutics, and Terns Pharmaceuticals Non Current Liabilities Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 10.2 M | 10.4 M | 9.8 M | 10.3 M | 9.3 M | 9.5 M |
| TERN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.5 M | 1.3 M |
| HEPA | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.4 M | 2.6 M | 2.6 M | 2.4 M | 2.6 M | 1.9 M | 2.1 M | 1.6 M | 2 M |
| VKTX | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 731 K | 360 K | 360 K | 360 K | 29 K | 1.3 M | 1.3 M | 1.1 M | 789.5 K |
| SRPT | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.2 M | 6.2 M | 5.9 M | 5.5 M | 15.6 M | 58 M | 814.4 M | 670.4 M | 36.9 M | 41.1 M | 39 M |
| PTCT | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2 M | 2 M | 335 K | 243 K | 338.3 M | 368.9 M | 1 B | 1 B | 971.9 M | 141 K | 133.9 K |
| DAWN | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 408 K | 469.2 K | 492.7 K |
| XFOR | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 9 K | 5 K | 16 K | 462 K | 826 K | 3.6 M | 432 K | 748 K |
| INZY | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 2.6 M | 1.9 M | 2.2 M | 2.2 M |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1 M | (1.0) | 34.3 K | 44 K | 62 K | 80 K | 182 K | 764 K | 802.2 K |
| ETNB | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 30 K | 687 K | 3.7 M | 3.9 M |
| PLRX | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 10 K | 2 K | 5.3 M | 3.4 M | 3.9 M | 4.1 M |
| ACLX | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 32 K | 19 K | 178 K | 178 K | 204.7 K | 214.9 K |
| STOK | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 4 K | 221 K | 422 K | 3.9 M | 3 M | 4.9 M | 5.1 M |
| KRYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 294 K | 294 K | 2.8 M | 3.3 M | 7 M | 7 M | 8 M | 8.4 M |
| IOVA | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 57.1 M | 65.5 M | 65.5 M | 75.3 M | 47.4 M |
Madrigal Pharmaceuticals and related stocks such as Intercept Pharmaceuticals, TG Therapeutics, and Terns Pharmaceuticals Non Current Liabilities Other description
My Equities
My Current Equities and Potential Positions
| Madrigal Pharmaceuticals | MDGL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 328.19
Check out Madrigal Pharmaceuticals Performance and Madrigal Pharmaceuticals Correlation. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Madrigal Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.